CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

  Iron IsomaltosideInjection (Monofer®) is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China, providing a better safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Iron Dextran Injection (Cosmofer®)is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the NEML. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, and will generateefficient synergies with the Group’s existing products across its key specialty areas, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive […]